Levodopa is a dopamine precursor used for Parkinson's disease and related parkinsonian disorders, and remains a core dopaminergic therapy. It is widely used as single-agent and in combinations such as carbidopa/levodopa formulations. Levodopa was first marketed in 1970.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
Serina Therapeutics has enrolled the first patient in its Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease in Australia, with dosing expected to begin in the first quarter of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07444892 |
Levodopa for Diabetic Retinopathy |
COMPLETED | PHASE2 |
| NCT06275633 |
Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD |
COMPLETED | NA |
| NCT06234995 |
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease |
RECRUITING | PHASE4 |
| NCT05901350 |
The Correlation of Reduction of Levodopa and Non-motor Symptoms of Parkinson's Disease After Deep Brain Stimulation |
COMPLETED | NA |
| NCT03235037 |
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome |
COMPLETED | NA |
| NCT03205956 |
Measuring Parkinson's Disease Progression |
COMPLETED | PHASE1 |
| NCT03119636 |
Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease |
UNKNOWN | PHASE1/PHASE2 |
| NCT03055936 |
Dose-finding Pharmacokinetic Study in Healthy Males |
COMPLETED | PHASE1 |
| NCT03000569 |
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease |
COMPLETED | PHASE2 |
| NCT02769793 |
Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON |
COMPLETED | PHASE4 |
